Mental and behavioral disorders due to crack use - dependency
Conditions
Interventions
Experimental group: 30 people with crack dependence will receive cannabidiol oil (CBD
50 mg / mL) - with oral daily dose of 600 mg, being 200 mg in the first and last week). Control group: 30 people with crack dependence will receive placebo oil (in equal quantity) and conventional tre
Sponsors
Universidade de Brasília, Faculdade de Ceilândia (UNB/FCE)
Universidade de Brasília, Faculdade de Ceilândia (UNB/FCE)
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Volunteers of both sexes; age between 18 and 65 years; on regular crack use in the last year on a daily basis or at least 20 times in the last 30 days; under treatment at the Center for Psychosocial Care alcohol and drugs (CAPS AD) of Ceilândia or indicated by persons under treatment in this service.
Exclusion criteria
Exclusion criteria: Presence of severe psychiatric comorbidities that impair the viability or safety of the study intervention; use of other medications directed to the treatment of severe or unstable chronic conditions (such as renal, cardiac, hepatic or neurological disease) and / or psychiatric comorbidities; hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products; pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of treatment expressed by adherence and compliance of steps by participants during the study period, and safety by the absence or mild manifestation of adverse effects.;Feasibility of treatment expressed by adherence and compliance of steps by participants during the study period, and safety by the absence or mild manifestation of adverse effects. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in the use of other drugs (in the case of polyusers) and in the mental and physical or behavioral health standard, evaluated by standardized questionnaires every 4 weeks (T0, T1 and T2);Maintenance of the effects obtained during the study after the end of the intervention (T3) | — |
Countries
Brazil
Contacts
Public ContactAndrea Gallassi
Universidade de Brasília, Faculdade de Ceilândia (UNB/FCE)
Outcome results
None listed